ABSTRACT Because of the putative rule of phospholipid methyltransferase reactions in many important membrane and receptor translocation processes, we studied the effect ofmethyltansferase inhibitors on acetylcholine receptor (AcChoR) turnover in cultured rat skeletal muscle. 
Methyltransferase inhibitor drugs may provide a therapeutic strategy in receptor disorders such as myasthenia gravis, in which accelerated receptor endocytosis plays a major role.
Membrane acetylcholine receptors (AcChoRs) are degraded by a mechanism that involves endocytosis and proteolysis (1, 2) . In myasthenia gravis (MG), a disorder attributable to a deficit of AcChoRs at neuromuscular junctions, degradation of AcChoRs is accelerated as a result of the action of anti-AcChoR antibody (3, 4) , which induces membrane redistribution and subsequent endocytosis of the receptor (5) (6) (7) . This accelerated endocytosis is one of the major pathogenetic mechanisms leading to AcChoR loss that corresponds with disease severity (8) . However, little is known about intrinsic membrane properties that might influence the rate of endocytosis of AcChoRs. Activation of phospholipid methyltransferase reactions is thought to alter the translocation of a variety of other membrane components, including distribution of f-adrenergic receptors in erythrocytes (9) , capping in lymphocytes (10) , exocytosis in mast cells (11, 12) , and endocytosis in fibroblasts (13) , perhaps due to altered membrane microviscosity (14) . Since phospholipid methyltransferases have been shown to be present in skeletal muscle (15, 16) , we postulated that methyltransferase reactions may play a role in the turnover of AcChoRs. We used a rat muscle culture system as a model to study normal and antibodyaccelerated degradation of AcChoRs. We found that specific inhibitors of methyltransferase reactions reduced the normal and pathologic turnover of AcChoRs and that this effect was partially reversed by the methyl donor methionine. This suggests an important role in skeletal muscle for phospholipid methyltransferases, the physiological function of which has previously been unknown. METHODS Skeletal Muscle Cultures. Cultures of rat skeletal muscle were prepared by conventional techniques as described (3, 17) . They were incubated under 1o0 CO2 in air at 370C in a medium consisting of Eagle's minimum essential medium with Earle's Salts (GIBCO) supplemented with 12.5% horse serum, 2.5% chicken embryo extract, penicillin (100 units/ ml), streptomycin (100 units/ml), and amphotericin B (2.5 ,ug/ml) (1) . Large numbers of dishes were prepared simultaneously to obtain matched sets of cultures with closely comparable numbers of AcChoRs.
Phospholipid Methylation Activity. Phospholipid methylation activity was assayed by the incorporation into phospholipids of 3H-methyl groups from L[methyl-3H]methionine (New England Nuclear; specific activity, 80 Ci/mmol; 1 Ci = 37 GBq) at a final L-methionine concentration of 113 IaM (100 juCi per dish). Cultures were incubated for 8 hr, and then labeled phospholipids were extracted, separated by TLC, and assayed for radioactivity as described (16) . The formation of phosphatidyl-N-monomethylethanolamine and phosphatidylcholine attributable to methyltransferase activity was calculated from the formula of Audubert and Vance (18) .
Effects of Pharmacologic Agents on AcChoRs in Skeletal Muscle Cultures. Methylation inhibitors used in these studies included 9-(3-D-ribofuranosyladenine (adenosine), L-homocysteine thiolactone hydrochloride, and sinefungin (all from Sigma) and etythro-9-[3-(2-hydroxynonyl)]adenine (EHNA) and 3-deazaadenosine (gifts from Burroughs Wellcome). L-Methionine (Sigma) was used to reverse inhibitor effects. Pharmacologic agents were diluted in culture medium without chicken embryo extract. Cultures were then incubated for 2-72 hr depending on the protocol (see below). Experiments were planned so that all cultures were the same age (8-9 days) at the time of analysis. The concentration of agents was adjusted to provide a maximal effect on AcChoR metabolism without altering cell integrity or other functions of the muscle cell (see below).
Total Surface AcChoRs. The number of surface AcChoR sites per culture was determined by '251-labeled a-bungarotoxin (125I-a-BuTx) binding. a-BuTx, obtained from the Miami Serpentarium, was repurified by ion-exchange chromatography using Whatman CM-32 columns prior to iodination and use (19) . At (1, 20) . All procedures were carried out at 370C. Parallel sets of at least five cultures were first saturated with 0.2 ptg of 125I-a-BuTx per ml for 30 min. The unbound toxin was then removed by washing four times with culture medium. At each of four subsequent 2-hr intervals, the medium and a single washing were removed to count the released radioactivity; fresh medium with pharmacologic agents (or without, for control cultures) was added to culture dishes. The initial 2-hr collection was discarded because of the possibility that it might contain washout of nonspecifically trapped 1251I-aBuTx. At the end of the turnover period, cultures were extracted with two washings of 2% Triton X-100 in phosphate-buffered saline (pH 7.2) to solubilize the remaining cell-bound 125I-a-BuTx-labeled AcChoRs, and the radioactivity in the extracts was counted. The apparent rate of degradation was calculated as the percentage of total radioactivity released into the medium per hour.
To evaluate the effects of pharmacologic agents on degradation of AcChoRs, culture media were made up to contain appropriate dilutions of each agent. Each medium was added to sets of 5-10 replicate culture dishes 2 hr prior to the AcChoR degradation assay. The medium was replaced immediately after labeling with 125I-a-BuTx and after each successive washing throughout the degradation procedure. To produce antibody-accelerated AcChoR degradation, the usual culture medium was supplemented with 20%o serum from a patient with MG whose anti-AcChoR antibody was known to produce marked acceleration of AcChoR degradation. Degradation rates were determined as described above. The method for measuring degradation of AcChoRs, in normal cultures and in those treated with human serum, has been validated previously (1, 3, 4, 21) .
AcChoR Synthesis and Insertion. AcChoR synthesis and insertion were evaluated by measuring the number of new AcChoRs appearing in skeletal muscle surface membrane in a 6-hr period, as described (20, 22) . Preexisting AcChoRs in skeletal muscle cultures were first blocked by incubation with unlabeled a-BuTx, and excess toxin was removed by repeated washings. The cultures were then incubated at 37TC for 6 hr and rinsed, and 125I-a-BuTx was added to label the new AcChoRs that had been inserted in the membrane during the preceding 6 hr. After washing, the cultures were extracted with 2% Triton X-100, and the radioactivity due to bound 1251-a-BuTx was measured in a y counter. The term "AcChoR synthesis," as used here, denotes the results obtained by this procedure.
To evaluate the effects of pharmacologic agents on AcChoR synthesis, culture media were made up to contain appropriate concentrations of each agent. These agents were added to replicate sets of seven cultures at 37°C for 2 hr. After this treatment, AcChoRs were blocked with a-BuTx, as above. The muscle cultures were then incubated at 37°C for 6 more hr in the presence of the test agents. AcChoRs that had been newly synthesized and inserted into the membrane during this period were then labeled with 125I-a-BuTx as above. Results are expressed as a percentage of the mean amount of synthesis and insertion determined simultaneously in untreated control cultures.
assayed by the incorporation of L- [4,5-3H] (10, 15) that had been shown to reduce phospholipid methylation in skeletal muscle by 54% (15) . This combination of 100 AuM adenosine, 100 ,M L-homocysteine, and 10 pM EHNA significantly reduced AcChoR degradation in skeletal muscle ( Table 1) . Combinations of two agents at a time produced small but statistically significant reductions in AcChoR degradation (data not shown).
To exclude nonspecific cytotoxic effects of components of the inhibitor, dose-seeking experiments were designed to find the greatest concentration ofeach component that by itselfhad no effect (Fig. 1) . Individually, adenosine at 50 JIM, Lhomocysteine at 100 pM, and EHNA at 8 A.M and below clearly had no effect on AcChoR degradation. The three agents were used in combination at these concentrations in all following experiments (referred to as the inhibitor "cocktail").
L-Homocysteine at 100 pM, ineffective by itself, was able to potentiate a significant inhibitory effect (P < 0.05) when combined with either 50 ,uM adenosine or 8 ,uM EHNA alone (data not shown). EHNA, ineffective at concentrations below 10 ,M, caused a dose-dependent inhibition of AcChoR degradation when potentiated by 100 ,uM L-homocysteine and adensosine (Fig. 2 Left) . Thus, the combination of all three agents (which singly had no effect) significantly reduced AcChoR degradation (P < 0.00001) (Fig. 2 Right).
In five muscle cultures, the effectiveness ofthe inhibitor on phospholipid methylation was measured directly. This cocktail effectively inhibited 3H-methyl incorporation into phos- Adenosine (6) phatidyl-N-monomethylethanolamine by >50%o and incorporation into phosphatidylcholine by >90%o (P < 0.01).
The effect ofthe methylation inhibitor cocktail on AcChoR degradation was sustained in culture for at least 72 hr (Fig. 3) Surface receptors. Agents may alter the apparent rate of AcChoR degradation by actually altering receptor endocytosis and degradation or merely by sequestering the labeled receptors and debris at internal sites without affecting the number of AcChoRs on the cell surface (7, 25) . To confirm that the methyltransferase inhibitor directly affected AcChoR endocytosis we measured its effect on the total remaining number of surface AcChoRs under normal conditions (Table 2 ). Within 8 hr ofincubation with the inhibitor cocktail, a trend toward increased surface receptors was measurable, and by 24-72 hr, the accumulation of surface AcChoRs was highly significant (P < 0.001).
AcChoR synthesis and insertion. Neither the inhibitor cocktail nor any of its component agents at concentrations up to 100 t&M adenosine, 100 uM L-homocysteine, or 10 jUM EHNA had any significant effect on AcChoR synthesis. From 16 to 34 replicate culture dishes were tested at each concentration in a total ofat least three separate experiments.
Protein synthesis.
[3H]Leucine incorporation was compared in replicate sets of 15 or more cultures treated with each of the following: the inhibitor, L-methionine (<1 mM), adenosine (s100 JIM), L-homocysteine (100 tLM), or EHNA (8 uM). A one-way analysis ofvariance showed no significant differences in protein synthesis among treatments (F = 0.84, P > 0.25; data not shown). Significance of difference from "no-inhibitor" condition: *P = 0.065, tp < 0.002, tP < 0.001. Cell morphology. In these experiments, no differences were observed in cell structure or the density of myotubes in cultures that were treated with different pharmacologic agents, as observed by phase-contrast microscopy.
Methionine Reverses the Effects of Methylation Inhibitor on AcChoR Degradation. If the inhibitor's effect on receptor turnover is mediated by competitive inhibition of methyltransferase reactions, then methionine should reverse the effect. By itself, L-methionine caused a slight but significant (P < 0.02) increase in the hourly rate ofdegradation of AcChoRs (Fig. 4) . Further, L-methionine significantly reversed >50%6 of the reduction in rate of AcChoR degradation produced by the inhibitor (P < 0.02). Incubation in L-methionine at a concentration of 1 mM for S-2 hr prior to the degradation assaysufficient to allow the production of S-adenosylmethioninewas required to produce these effects.
By contrast, the rate of synthesis and insertion ofAcChoRs was unaffected by L-methionine at concentrations of 0.5-10 mM.
Role of Methyltransferase Reactions in Accelerated AcChoR Degradation Induced by Myasthenic Serum. Serum from a patient with MG markedly increased the AcChoR degradation rate by 2.8-fold (Fig. 5) . The methyltransferase inhibitor cocktail significantly reduced this accelerated degradation rate by 23% + 3% (P < 0.00001). Again, L-methionine significantly reversed 40% of that inhibition (P = 0.05).
To confirm that the methyltransferase inhibitor directly affected AcChoR endocytosis, we measured its effect on the total remaining number of surface AcChoRs under antibodyaccelerated conditions (Table 2 ). In the presence of antiAcChoR antibody, rat skeletal muscle fibers in culture lose two-thirds of their AcChoRs within 8 hr. The inhibitor cocktail significantly increased total surface receptors under these conditions (P < 0.001).
DISCUSSION
These studies were designed to explore whether methyltransferase reactions are involved in AcChoR turnover. We have shown that methyltransferase inhibitors reduce the normal turnover of AcChoRs and the antibody-accelerated degradation of receptors induced by myasthenic immunoglobulin. The effect of methyltransferase inhibitors on AcChoR turnover appears specifically limited to reduction in the rate of endocytosis and subsequent degradation, without an apparent change adenosine, 100 MM L-homocysteine, 10 ,uM EHNA) concentrations of the inhibitor were compared with replicates to which 1000 AM L-methionine was added. Data are presented as mean ± SEM. All treatments were significantly different from the no-methionine control at least at the P < 0.02 level. AChR, AcChoR. *, Significantly increased degradation rates compared to paired condition without methionine, P < 0.02. Effect of methyltransferase inhibitor on accelerated degradation of AcChoRs (AChRs). Cultures, which were incubated with myasthenic serum containing anti-AcChoR antibody to accelerate AcChoR degradation, were also treated with the methyltransferase inhibitor cocktail. These inhibited cultures were also compared with replicate cultures treated with 10 mM L-methionine (shaded). Data are presented as mean ± SEM. *, Significantly inhibited compared to myasthenic serum alone (P < 0.0001). t, Significantly increased degradation rate compared to paired condition without methionine (P = 0.05).
in AcChoR synthesis and insertion and without nonspecific metabolic or morphologic effects. Further, the effect is longlasting in cultured muscle cells. Since the result is an increase in the number of surface receptors, the implied mechanism of the inhibitor's action is reduction of endocytosis.
The experimental strategy we used relied on the ability to inhibit methyltransferases specifically. S-Adenosylhomocysteine produced during methylation reactions is itself a competitive inhibitor. Ordinarily, hydrolysis of S-adenosylhomocysteine to adenosine and homocysteine acts as a sink for this inhibitor. Since the S-adenosylhomocysteine hydrolysis is reversible, the intracellular levels of S-adenosylhomocysteine can be increased by incubating muscle in adenosine, Lhomocysteine, or the adenosine deaminase inhibitor EHNA.
The combination of all three greatly increases S-adenosylhomocysteine levels, potently inhibiting methyltransferase reactions. Our hypothesis that methylation reactions occurring in skeletal muscle (16) also unaffected by the concentrations of the inhibitor components used. (iii) A muscle-specific control was provided by the fact that synthesis of the AcChoR itself was unaffected by the methyltransferase inhibitor or its components. (iv) The inhibitor components at threshold concentrations had no independent effect on AcChoR degradation, but their inhibitory effect was potentiated in combination. (v) Other methylation inhibitors gave similar effects. All of these findings, taken together, strongly suggest that the inhibitor produces its effect by specifically altering methylation of a muscle substrate. Alternate inhibitory effects, for example, as mediated through expected changes in adenosine or adenine nucleotide levels, are very unlikely. The fact that L-methionine consistently counteracted the inhibitor-induced reduction in AcChoR degradation suggests that the effect occurred by specific competitive inhibition of a methyltransferase reaction. Similarly, the fact that an adenosine deaminase inhibitor by itself did not affect AcChoR degradation at low (2-10 ,LM) concentrations yet over the same concentration range gave a dose-related inhibition of AcChoR degradation when potentiated by homocysteine and adenosine again suggests a specific methylation effect.
Phospholipids or proteins can each serve as methyltransferase substrates. It seems that alteration of phospholipid methylation in membranes might be the most likely to affect the pathway of endocytotic degradation of receptors. This idea has been directly tested in fibroblast experiments (13) in which the phospholipid polar head group composition of fibroblast membranes was altered to enrich the proportion of phosphatidylcholine, phosphatidyl-N,N-dimethylethanolamine, and phosphatidyl-N-monomethylethanolamine. The degree of methylation of the phospholipid polar head group correlated positively with the rate of phagocytosis and pinocytosis, so that phagocytosis of beads and pinocytosis of horseradish peroxidase were depressed when phospholipids were less methylated. A proposed mechanism is increased membrane microfluidity produced by methylation of phosphatidylethanolamine (14) . In our experiments, the reduction of AcChoR turnover coincided with significantly reduced methylation of phospholipids. Although proteins are substrates for N-methyltransferases, and the AcChoR can itself be methylated (26) , this is an unlikely mechanism for the effect of the inhibitors on AcChoR degradation. It has been reported that inhibition of protein methylation alters none of the important functions of the AcChoR acutely, including resting membrane potential, AcCho-induced depolarization, or desensitization (27) . This in fact provides an external control for our studies, suggesting that only the turnover, not the function, of the AcChoR is affected by methylation inhibitors. The question of whether the effect of methyltransferase inhibitors on AcChoR degradation occurs because of inhibited phospholipid (as opposed to protein) methylation can be tested by use of a battery of methyltransferase inhibitors that have relatively strict substrate specificity. Sinefungin, which is several orders of magnitude more potent as a protein methyltransferase inhibitor than it is as a lipid methyltransferase inhibitor, was completely ineffective in our systems even at high concentrations. On the contrary, 3-deazaadenosine and periodate-oxidized adenosine are rather specific inhibitors of phospholipid methylation (28) , and both are potent inhibitors of AcChoR degradation (unpublished observations).
In addition to indicating a physiologic role for the phospholipid methyltransferase reactions in normal turnover of AcChoRs, these studies have suggested that the pathologic loss of surface receptors may also be influenced by phospholipid methylation. In MG, loss of surface receptors is mediated by anti-AcChoR antibody by way of several mechanisms; accelerated endocytosis of receptors appears to be an important mechanism (7) and one that is functionally relevant in the clinical expression of disease (8) . Current therapy of MG is directed at acetylcholinesterase inhibition, generalized immunosuppression, and thymectomy, and perhaps, in the future, at specific immunoregulatory alteration, but no therapy has specifically targeted the important pathogenic mechanism of endocytosis. The physiologic role of methyltransferase reactions in membrane receptor turnover demonstrated here offers a potential strategy for altering disordered receptor turnover in MG. Further, the methyltransferase inhibitor strategy may be applicable to other receptor disorders or disorders in which endocytosis plays a prominent role.
